Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma.

OBJECTIVE To examine the relationship between the configuration of the drainage angle and intraocular pressure (IOP)-lowering efficacy of latanoprost in subjects with chronic angle-closure glaucoma (CACG). DESIGN Prospective observational case series. PARTICIPANTS One hundred thirty-seven Asian subjects with CACG. METHODS Study subjects had participated in a 12-week, randomized, double-masked study that assessed the IOP-reducing effect of latanoprost. Chronic angle-closure glaucoma was defined as optic neuropathy with or without a visual field defect, an anterior chamber angle in which the trabecular meshwork was not visible for at least 180 degrees on gonioscopy, and evidence of peripheral anterior synechiae (PAS) in association with a chronically elevated IOP. Static and dynamic gonioscopy was performed at baseline. The angles were graded in each quadrant according to the Shaffer scheme, and the number of clock hours of PAS was recorded. The change in daily IOP (defined as the mean of the 9:00 am and 5:00 pm IOP time point values) from baseline to week 12 was analyzed and correlated with mean angle width and extent of PAS. RESULTS One hundred thirty-seven Asian subjects with CACG completed the study in the latanoprost-treated group. Most subjects were female (75%), and the mean age was 62.6+/-9.4 years. At baseline, the mean angle width was 0.84+/-0.55, and the mean number of clock hours of PAS was 4.67+/-2.95. After 12 weeks of treatment, latanoprost reduced IOP from 25.0+/-5.5 mmHg to 17.5+/-5.0 mmHg (P<0.001). The percent change in IOP produced by latanoprost was not associated with mean angle width (Spearman's r = 0.04, P = 0.64) or the number of clock hours of PAS (Spearman's r = -0.15, P = 0.08). CONCLUSIONS In subjects with CACG, the IOP-reducing efficacy of latanoprost was not affected by the degree of angle narrowing or extent of synechial angle closure.

[1]  P. Kaufman,et al.  Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. , 1999, Archives of ophthalmology.

[2]  D. Machin,et al.  The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. , 2000, Archives of ophthalmology.

[3]  T. Aung,et al.  Long-term clinical course of primary angle-closure glaucoma in an Asian population. , 2000, Ophthalmology.

[4]  P. Kaufman,et al.  Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. , 2001, Archives of ophthalmology.

[5]  M. Araie,et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. , 1996, Archives of ophthalmology.

[6]  J. Stjernschantz,et al.  A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. , 1996, Ophthalmology.

[7]  P. Hung,et al.  Provocation and mechanism of angle-closure glaucoma after iridectomy. , 1979, Archives of ophthalmology.

[8]  R K John,et al.  Angle-closure glaucoma in an urban population in southern India. The Andhra Pradesh eye disease study. , 2000, Ophthalmology.

[9]  R. Weinreb,et al.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. , 1997, Investigative ophthalmology & visual science.

[10]  A. Alm,et al.  Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. , 1993, Ophthalmology.

[11]  Y. F. Chen,et al.  Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  R. Weinreb,et al.  Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. , 1997, Survey of ophthalmology.

[13]  C. Camras Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. , 1996, Ophthalmology.

[14]  Y. Chan,et al.  Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study. , 2000, Ophthalmology.

[15]  R. Lowe Persistent symptoms after peripheral iridectomy for angle-closure glaucoma. , 1987, Australian and New Zealand journal of ophthalmology.

[16]  P. Foster,et al.  Glaucoma in Mongolia. A population-based survey in Hövsgöl province, northern Mongolia. , 1996, Archives of ophthalmology.

[17]  R. Hitchings,et al.  Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. , 1993, Ophthalmology.

[18]  A. Alm,et al.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. , 1995, Ophthalmology.

[19]  P. Kaufman,et al.  Effects of prostaglandins on the aqueous humor outflow pathways. , 2002, Survey of ophthalmology.

[20]  R. Ritch,et al.  Chronic angle-closure with glaucomatous damage: long-term clinical course in a North American population and comparison with an Asian population. , 2002, Ophthalmology.

[21]  R. Brubaker,et al.  The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. , 1993, Archives of ophthalmology.

[22]  T. Aung,et al.  Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. , 2004, Ophthalmology.

[23]  M. Yablonski,et al.  Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes , 1993 .